Use of Lemborexant for Insomnia in Our Clinic: A Retrospective Study

Use of Lemborexant for Insomnia in Our Clinic: A Retrospective Study - Use of Lemborexant for Insomnia in Our Clinic: A Retrospective Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054075

Enrollment

1000

Registered

2024-04-06

Start date

2024-04-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who visited our clinic between April 2022 and March 2024 2.Patients diagnosed with insomnia and prescribed Lemborexant at their initial visit 3.Patients with no history of Lemborexant use prior to their first consultation 4.Adult patients aged 18 years and older

Exclusion criteria

Exclusion criteria: 1.Patients diagnosed with sleep disorders other than insomnia 2.Patients who were administered other insomnia medications or had their Lemborexant dosage changed within 4 weeks from the initial consultation

Design outcomes

Primary

Measure	Time frame
This study evaluates the impact of Lemborexant treatment on patients' sleep latency, number of nocturnal awakenings, frequency of early morning awakenings, and sleep quality. Additionally, the efficacy of Lemborexant will be assessed using the Athens Insomnia Scale (AIS).	—

Countries

Japan

Contacts

Public ContactHinako Imamura

General Clinic General Clinic

info@nemuri.jp0666842558

Outcome results